The combined effect of retinoic acid and LSD1 siRNA inhibition on cell death in the human neuroblastoma cell line SH-SY5Y

Cellular Physiology and Biochemistry

Volumn 31, Issue 6, 2013, Pages 854-862

  Xu, Guofeng ^a   Xiao, Yongtao ^b   Hu, Jimeng ^a   Xing, Lili ^a   Zhao, Ou ^a   Wu, Yeming ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Institute for Pediatric Research   (China)

Author keywords

Apoptosis; Lysine specific demethylase 1; Neuroblastoma; Retinoic acid; SH SY5Y cell line

Indexed keywords

BIOLOGICAL MARKER; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LYSINE SPECIFIC DEMETHYLASE 1; NERVE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; RETINOIC ACID; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MALE; NERVE CELL NECROSIS; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCHOOL CHILD;

EID: 84879467883     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000350103     Document Type: Article

References (34)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL: Neuroblastoma. Lancet 2007;369:2106-2120.
2. Brodeur GM: Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-216.
3. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent J: Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983;305:245-248.
4. Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, Brodeur GM, Cohn SL, Matthay KK, Maris JM, Children's Oncology G: Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Eng J Med 2005;353:2243-2253.
5. Diskin SJ, Hou C, Glessner JT, Attiyeh EF, Laudenslager M, Bosse K, Cole K, Mosse YP, Wood A, Lynch JE, Pecor K, Diamond M, Winter C, Wang K, Kim C, Geiger EA, McGrady PW, Blakemore AI, London WB, Shaikh TH, Bradfield J, Grant SF, Li H, Devoto M, Rappaport ER, Hakonarson H, Maris JM: Copy number variation at 1q21.1 associated with neuroblastoma. Nature 2009;459:987-991.
6. Kushner BH, Kramer K, LaQuaglia MP, Modak S, Yataghene K, Cheung NK: Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol 2004;22:4888-4892.
7. McCaffery PJ, Adams J, Maden M, Rosa-Molinar E: Too much of a good thing: Retinoic acid as an endogenous regulator of neural differentiation and exogenous teratogen. Eur J Neurosci 2003;18:457-472.
8. Ross SA, McCaffery PJ, Drager UC, De Luca LM: Retinoids in embryonal development. Physiol Rev 2000;80:1021-1054.
9. Lippman SM, Lotan R: Advances in the development of retinoids as chemopreventive agents. J Nutr 2000;130:479S-482S.
10. Thiele CJ, Reynolds CP, Israel MA: Decreased expression of n-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985;313:404-406.
11. Melino G, Thiele CJ, Knight RA, Piacentini M: Retinoids and the control of growth/death decisions in human neuroblastoma cell lines. J Neurooncol 1997;31:65-83.
12. van Noesel MM, Versteeg R: Pediatric neuroblastomas: Genetic and epigenetic 'danse macabre'. Gene 2004;325:1-15.
13. Cernaianu G, Brandmaier P, Scholz G, Ackermann OP, Alt R, Rothe K, Cross M, Witzigmann H, Trobs RB: All-trans retinoic acid arrests neuroblastoma cells in a dormant state. Subsequent nerve growth factor/brain-derived neurotrophic factor treatment adds modest benefit. J Pediatr Surg 2008;43:1284-1294.
14. Messi E, Florian MC, Caccia C, Zanisi M, Maggi R: Retinoic acid reduces human neuroblastoma cell migration and invasiveness: Effects on dcx, lis1, neurofilaments-68 and vimentin expression. BMC Cancer 2008;8:30.
15. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y: Histone demethylation mediated by the nuclear amine oxidase homolog lsd1. Cell 2004;119:941-953.
16. Liu F, Quesada V, Crevillen P, Baurle I, Swiezewski S, Dean C: The arabidopsis rna-binding protein fca requires a lysine-specific demethylase 1 homolog to downregulate flc. Mol Cell 2007;28:398-407.
17. Mosammaparast N, Shi Y: Reversal of histone methylation: Biochemical and molecular mechanisms of histone demethylases. Annu Rev Biochem 2010;79:155-179.
18. Chen Y, Jie W, Yan W, Zhou K, Xiao Y: Lysine-specific histone demethylase 1 (lsd1): A potential molecular target for tumor therapy. Crit Rev Eukaryot Gene Expr 2012;22:53-59.
19. Lim S, Janzer A, Becker A, Zimmer A, Schule R, Buettner R, Kirfel J: Lysine-specific demethylase 1 (lsd1) is highly expressed in er-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 2010;31:512-520.
20. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Chen S, Nelson PS, Liu XS, Brown M, Balk SP: Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 2011;20:457-471.
21. Wu CY, Hsieh CY, Huang KE, Chang C, Kang HY: Cryptotanshinone down-regulates androgen receptor signaling by modulating lysine-specific demethylase 1 function. Int J Cancer 2012;131:1423-1434.
22. Xie D, Sham JS, Zeng WF, Lin HL, Che LH, Wu HX, Wen JM, Fang Y, Hu L, Guan XY: Heterogeneous expression and association of beta-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer 2003;107:896-902.
23. Cai MY, Zhang B, He WP, Yang GF, Rao HL, Rao ZY, Wu QL, Guan XY, Kung HF, Zeng YX, Xie D: Decreased expression of pinx1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma. Cancer Sci 2010;101:1543-1549.
24. Zlobec I, Steele R, Michel RP, Compton CC, Lugli A, Jass JR: Scoring of p53, vegf, bcl-2 and apaf-1 immunohistochemistry and interobserver reliability in colorectal cancer. Mod Pathol 2006;19:1236-1242.
25. Castel V, Canete A: A comparison of current neuroblastoma chemotherapeutics. Expert Opin Pharmacother 2004;5:71-80.
26. Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, Field HI, Neal DE, Yamaue H, Ponder BA, Nakamura Y, Hamamoto R: Overexpression of lsd1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 2011;128:574-586.
27. Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, Ora I, Pajtler K, Klein-Hitpass L, Kuhfittig-Kulle S, Metzger E, Schule R, Eggert A, Buettner R, Kirfel J: Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: Implications for therapy. Cancer Res 2009;69:2065-2071.
28. Papucci L, Witort E, Bevilacqua AM, Donnini M, Lulli M, Borchi E, Khabar KS, Tempestini A, Lapucci A, Schiavone N, Nicolin A, Capaccioli S: Impact of targeting the adenine-and uracil-rich element of bcl-2 mrna with oligoribonucleotides on apoptosis, cell cycle, and neuronal differentiation in shsy-5y cells. Mol Pharmacol 2008;73:498-508.
29. Shimizu S, Narita M, Tsujimoto Y: Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel vdac. Nature 1999;399:483-487.
30. Murphy KM, Ranganathan V, Farnsworth ML, Kavallaris M, Lock RB: Bcl-2 inhibits bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells. Cell Death Differ 2000;7:102-111.
31. Adams JM, Cory S: The bcl-2 protein family: Arbiters of cell survival. Science 1998;281:1322-1326.
32. Lasorella A, Iavarone A, Israel MA: Differentiation of neuroblastoma enhances bcl-2 expression and induces alterations of apoptosis and drug resistance. Cancer Res 1995;55:4711-4716.
33. Schenk T, Chen WC, Gollner S, Howell L, Jin L, Hebestreit K, Klein HU, Popescu AC, Burnett A, Mills K, Casero RA, Jr., Marton L, Woster P, Minden MD, Dugas M, Wang JC, Dick JE, Muller-Tidow C, Petrie K, Zelent A: Inhibition of the lsd1 (kdm1a) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nature Med 2012;18:605-611.
34. Glasow A, Barrett A, Petrie K, Gupta R, Boix-Chornet M, Zhou DC, Grimwade D, Gallagher R, von Lindern M, Waxman S, Enver T, Hildebrandt G, Zelent A: DNA methylation-independent loss of rara gene expression in acute myeloid leukemia. Blood 2008;111:2374-2377.